Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
$1.99
per week
for 24 weeks
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Michele Romanow, who is a Canadian technology entrepreneur, television personality and venture capitalist, at her Toronto home on Sept. 26, 2016.

Michelle Siu/The Globe and Mail

Canadian early-stage companies, riding a wave of pandemic-related interest and demand, raised a record amount of venture capital in the first quarter, the Canadian Venture Capital and Private Equity Association reported Tuesday.

The CVCA said Canadian companies raised $2.7-billion in venture capital over 175 deals in the period. That’s up sharply from the $831-million raised in 117 deals in the same quarter a year ago, which was affected as the pandemic shut down economies in March.

Eight deals in the quarter were valued at $100-million or more, including financings for Michele Romanow’s Clear Finance Technology Corp. and online travel firm Hopper Inc. They are among a slew of Canadian early-stage companies in recent months to reach “unicorn status” by achieving valuations of US$1-billion or more.

Story continues below advertisement

Financing for Canadian innovators has continued at a strong pace in the second quarter, with significant announced venture funding for Wealthsimple Technologies Inc., Ada Support Inc., Clio and Knix Wear Inc., among others, and initial public offerings by Magnet Forensics Inc. and Thinkific Labs Inc. Despite recent market volatility that has cut into valuations for technology vendors, several Canadian companies, including Q4 Inc., VerticalScope Inc., Softchoice Corp. and Maple, are all eyeing potential IPOs in the near term.

Funding for Canada’s ascendant biotechnology sector was strong, at $324-million in the quarter, putting it on track for a third consecutive year of US$1-billion-plus in venture capital raised. The biggest share of funding, or $1.3-billion, went to information and communications technology companies.

The first quarter also included several prominent “exits,” including the closing of Nasdaq Inc. ’s purchase of fraud detection software firm Verafin Inc., telemedicine provider Dialogue Health Technologies Inc. ’s IPO and a buyout of Tandem Expansion’s stake in Coveo Solutions by the Qatar Investment Authority for $130-million, the CVCA said.

CVCA chief executive officer Kim Furlong said, “What we’re hearing over and over is that capital is no longer the issue; there is capital if you require it. It tells you we’re going to have another fabulous year” in 2021.

The domestic VC industry is also set to get a boost after the federal government committed in April’s budget to a third $400-million program to boost the sector. Ms. Furlong said she wasn’t worried about valuations overheating, “but I agree that there are a lot of dollars at play.”

The CVCA numbers reiterate similar findings this month from Refinitiv, which also found Canadian venture capital had its most active quarter on record as measured by amount invested.

The CVCA also reported Tuesday that while private-equity investment activity was the highest on record, at 177 deals, the amount invested was relatively low, at $2.68-billion. However, the CVCA said 2021 will likely set the record for most private-equity-backed IPOs in Canada, with two in the first quarter and several others since completed or in progress, including offerings by Dentalcorp Holdings Ltd. and Softchoice Corp.

Story continues below advertisement

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies